Literature DB >> 28104154

Cost Analysis of Transplantation in Japan, Performed With the Use of the National Database.

T Kitazawa1, K Matsumoto1, S Fujita1, K Seto1, T Hasegawa2.   

Abstract

BACKGROUND: When assessing the cost of transplants in Japan, earlier studies have been limited to case series that investigated inpatient cost alone. Few studies have evaluated total cost, which includes inpatient, outpatient, and pharmaceutical costs, or compared costs before and after transplantation. Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), we investigated the total cost of major transplantation and contributing factors.
METHODS: We analyzed the cost and complications of patients who underwent a cadaveric renal transplantation (CRT), living renal transplantation (LRT), living-donor liver transplantation (LDLT), allogeneic bone marrow transplantation, autologous bone marrow transplantation, allogeneic peripheral blood stem cell transplantation, or autologous peripheral blood stem cell transplantation (auto-PBSCT) from April 2009 to March 2010.
RESULTS: The highest total cost of the month of transplantation was 4.95 million yen (JPY) for LDLT. Among renal transplantations, the cost of CRT was higher than LRT (3.69 vs 3.55 million JPY). Recipients of auto-PBSCT complicated by graft-versus-host disease, urinary tract infection, sepsis, or pneumonia had a significantly higher average total cost during the month of transplantation and the 2 following months than patients without it, as well as statistically longer total treatment days.
CONCLUSIONS: In Japan, almost all medical services are covered by national health insurance, and the Japan government has begun to allow the use of the NDB for research activities. This is the first study to use the NDB to analyze the cost of transplantation, with technical and institutional limitations.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28104154     DOI: 10.1016/j.transproceed.2016.10.007

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

Review 1.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

2.  Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.

Authors:  Chihiro Yamamoto; Hirotomo Nakashima; Takashi Ikeda; Shin-Ichiro Kawaguchi; Yumiko Toda; Shoko Ito; Kiyomi Mashima; Takashi Nagayama; Kento Umino; Daisuke Minakata; Hirofumi Nakano; Kaoru Morita; Ryoko Yamasaki; Miyuki Sugimoto; Yuko Ishihara; Masahiro Ashizawa; Kaoru Hatano; Kazuya Sato; Iekuni Oh; Shin-Ichiro Fujiwara; Masuzu Ueda; Ken Ohmine; Kazuo Muroi; Yoshinobu Kanda
Journal:  Blood Adv       Date:  2019-11-12

Review 3.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

4.  Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data.

Authors:  Sigrid M Mohnen; Manon J M van Oosten; Jeanine Los; Martijn J H Leegte; Kitty J Jager; Marc H Hemmelder; Susan J J Logtenberg; Vianda S Stel; Leona Hakkaart-van Roijen; G Ardine de Wit
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

5.  Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database.

Authors:  Yasuhisa Ono; Yusuke Taneda; Tomomi Takeshima; Kosuke Iwasaki; Atsutaka Yasui
Journal:  Clin Epidemiol       Date:  2020-04-08       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.